NCT-501

Name: NCT-501
Brand: MedChemExpress
SKU: HY-18768
Rating: 5.0 (5 reviews)

Cat. No.: HY-18768 Purity: 99.59%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

NCT-501 is a reversible, non-competitive, selective, blood-brain barrier-permeable ALDH1A1 inhibitor with an IC₅₀ of 40 nM. NCT-501 inhibits the AKT-β-catenin signaling pathway, induces necroptosis in nasopharyngeal carcinoma cells, suppresses their proliferation and inhibits stem cell spheroid formation. NCT-501 can be used in research related to nasopharyngeal carcinoma, esophageal squamous cell carcinoma and malignant tumors.

For research use only. We do not sell to patients.

CAS No. : 1802088-50-1

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of NCT-501:

NCT-501 hydrochloride Get quote

5 Publications Citing Use of MCE NCT-501

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

In Vivo Imaging

: NCT-501 purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2020 Jan;19(1):199-210. [Abstract]; The ALDH1A1 inhibitor NCT-501 synergistically augments the cytotoxicity of olaparib in BRCA2-deficient EOC cell lines. PEO1 and Kuramochi cells were treated with olaparib, NCT-501, or olaparib+NCT-501 for 7 days, cell viability was determined using the methylene blue assay.

: NCT-501 purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2020 Jan;19(1):199-210. [Abstract]; PEO1-R cells (2 × 10⁶) were injected into nude mice subcutaneously to generate xenografts, treated with olaparib (50 mg/kg, once a day) or/and NCT-501 (10 mg/kg, once a day) intraperitoneally for 8 days. Tumor volumes were determined using caliber every other day.

: NCT-501 purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2020 Jan;19(1):199-210. [Abstract]; PEO1 cells containing luciferase expression vector (2 × 10⁶) were injected into nude mice intraperitoneally to generate xenografts, treated with olaparib (50 mg/kg, once a day) or/and NCT-501 (10 mg/kg, once a day) intraperitoneally for 10 days. Tumor volumes were determined using BLI.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Aldehyde Dehydrogenase (ALDH) Isoform Specific Products:

View All Isoforms

ALDH1 ALDH2 ALDH3

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

ALDH1

Cellular Effect

Cell Line	Type	Value	Description	References
OV-90	EC₅₀	43.9 μM Compound: 4	Cytotoxicity against 3D culture of human OV90 cells assessed as decrease in cell viability after 6 days by CellTiter-Glo assay Cytotoxicity against 3D culture of human OV90 cells assessed as decrease in cell viability after 6 days by CellTiter-Glo assay	[PMID: 29767973]

In Vitro

NCT-501 inhibits stem cell spheroid formation in human nasopharyngeal carcinoma SUNE1 cells^[1].
NCT-501 (log₁₀ 1.0-log₁₀ 2.5 μM; five days) reduces cell viability in human nasopharyngeal carcinoma 5-8F, 6-10B, SUNE1, and HK1 cells with IC₅₀ values of 96.91 μM, 64.15 μM, 27.84 μM, and 67.97 μM respectively, with greater sensitivity in cells with higher ALDH1A1 expression^[1].
NCT-501 (14 days) inhibits colony formation in human nasopharyngeal carcinoma 6-10B and SUNE1 cells^[1].
NCT-501 induces necroptosis in human nasopharyngeal carcinoma SUNE1 cells, as evidenced by caspase-independent cell death, characteristic nuclear and ultrastructural changes, and HMGB1 translocation^[1].
NCT-501 downregulates ALDH1A1 expression and inhibits components of the AKT-β-catenin signaling pathway in TE-1 esophageal squamous cell carcinoma cells, with significant reductions in ALDH1A1 and AKT1 protein levels to ~0.4 relative to β-actin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	C_max	T_1/2 (Plasma)	AUC_0-24	Bioavailability	C_max (Brain)	T_1/2 (Brain)	T_1/2	V_ss	CL
Mice^[3]	2 mg/kg	i.v.	2070 ng/mL	/	332 ng·h/mL	/	/	/	0.5 h	1.8 L/kg	98 mL/min/kg
Mice^[3]	30 mg/kg	i.p.	8080 ng/mL	/	5670 ng·h/mL	100 %	/	/	0.7 h	/	/
Mice^[3]	10 mg/kg	p.o.	696 ng/mL	0.4 h	484 ng·h/mL	29 %	1130 ng/mL	0.4 h	/	/	/

In Vivo

Animal Model:	5-6 weeks old male Hsd: Athymic Nude-Foxn1nu (immuno-deficient-mice bearing Cal-27 CisR cells)^[1]
Dosage:	100µg/animal
Administration:	Intra-tumorally (i.t); every alternate day for 20 days
Result:	Showed a 78% inhibition in tumor growth in Cal-27 CisR derived xenografts.

Molecular Weight

416.52

Formula

C₂₁H₃₂N₆O₃

CAS No.

1802088-50-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(N1C)N(C)C2=C(N(CCC(C)C)C(CN3CCN(C(C4CC4)=O)CC3)=N2)C1=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 3.57 mg/mL (8.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4008 mL	12.0042 mL	24.0085 mL
5 mM	0.4802 mL	2.4008 mL	4.8017 mL
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.00 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (3.00 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.59%

Select Batch:

Data Sheet (278 KB) SDS (251 KB)

COA (252 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Wang H, et al. Targeting ALDH1A1 to induce Necroptosis in Nasopharyngeal Carcinoma. J Cancer. 2022;13(14):3515-3525. Published 2022 Oct 24.

[2]. Wang W, et al. ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin. Biomed Pharmacother. 2020;125:109940.

[3]. Yang SM, et al. Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1). J Med Chem. 2015 Aug 13;58(15):5967-78.
[Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4008 mL	12.0042 mL	24.0085 mL	60.0211 mL
DMSO	5 mM	0.4802 mL	2.4008 mL	4.8017 mL	12.0042 mL

NCT-501 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

NCT-501

Customer Review

Other Forms of NCT-501:

NCT-501 Related Antibodies

5 Publications Citing Use of MCE NCT-501

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Aldehyde Dehydrogenase (ALDH) Isoform Specific Products:

View All Akt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

NCT-501 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

NCT-501 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report